Загрузка...
COVID-19 and the nicotinic cholinergic system
The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S
Сохранить в:
| Опубликовано в: : | Eur Respir J |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
European Respiratory Society
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7248130/ https://ncbi.nlm.nih.gov/pubmed/32444400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01589-2020 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|